J. Goldman & Co’s Vanda Pharmaceuticals VNDA Stock Holding History

J. Goldman & Co’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-140,647	Closed	-$2.87M	–	398
2018 Q2	$2.68M	Sell	140,647 -62,001	-31%	-$1.04M	0.14%	187
2018 Q1	$3.42M	Buy	+202,648	New	+$3.39M	0.15%	166
2016 Q3	–	Sell	-463,900	Closed	-$5.19M	–	413
2016 Q2	$5.19M	Sell	463,900 -407,100	-47%	-$3.94M	0.27%	87
2016 Q1	$7.28M	Sell	871,000 -31,839	-4%	-$261K	0.45%	65
2015 Q4	$8.4M	Buy	902,839 +421,079	+87%	+$4.2M	0.87%	26
2015 Q3	$5.43M	Sell	481,760 -264,424	-35%	-$3.23M	0.47%	69
2015 Q2	$9.47M	Buy	746,184 +161,899	+28%	+$1.75M	0.57%	48
2015 Q1	$5.43M	Buy	584,285 +307,112	+111%	+$3.47M	0.34%	89
2014 Q4	$3.97M	Sell	277,173 -695,327	-71%	-$8.23M	0.47%	69
2014 Q3	$10.1M	Buy	972,500 +868,750	+837%	+$11.4M	0.61%	43
2014 Q2	$1.68M	Buy	+103,750	New	+$1.38M	0.12%	161
2014 Q1	–	Sell	-59,000	Closed	-$732K	–	304
2013 Q4	$732K	Sell	59,000 -21,000	-26%	-$211K	0.09%	179
2013 Q3	$876K	Sell	80,000 -87,000	-52%	-$930K	0.08%	206
2013 Q2	$1.35M	Buy	+167,000	New	+$1.12M	0.14%	168

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

J. Goldman & Co's VNDA Position: Q3 2018 in Review

J. Goldman & Co sold out of Vanda Pharmaceuticals (VNDA) in Q3 2018, closing a stake of 140,647 shares — an estimated $2.87M sold.

J. Goldman & Co first reported a position in VNDA in Q2 2013 and held it in 14 quarters. The position peaked at $10.1M in Q3 2014. 160 funds tracked by Wall St. Rank hold VNDA as of Q3 2018.

J. Goldman & Co reported no remaining Vanda Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
J. Goldman & Co sold 140,647 Vanda Pharmaceuticals shares in Q3 2018, an estimated $2.87M.
J. Goldman & Co first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 14 quarters.
J. Goldman & Co's Vanda Pharmaceuticals position peaked at $10.1M in Q3 2014.
160 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2018.

Based on J. Goldman & Co's 13F filing for Q3 2018, filed 14 Nov 2018.